Alzheimer’s group amps public pressure with ad campaign as Medicare decision looms
A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs.
UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare and Medicaid Services’ proposed decision to only cover Biogen and Eisais’s Aduhelm and other potential anti-beta amyloid drugs for patients in clinical trials. CMS’ final decision is set for release on April 11.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
